Identification of 2-oxo-N-(phenylmethyl)-4-imidazolidinecarboxamide antagonists of the P2X7 receptor

https://doi.org/10.1016/j.bmcl.2010.09.101Get rights and content

Abstract

A backup molecule to compound 2 was sought by targeting the most likely metabolically vulnerable site in this molecule. Compound 18 was subsequently identified as a potent P2X7 antagonist with very low in vivo clearance and high oral bioavailability in all species examined. Some evidence to support the role of P2X7 in the etiology of pain is also presented.

References and notes (32)

  • G. Collo et al.

    Neuropharmacology

    (1997)
  • L.J. Chambers et al.

    Bioorg. Med. Chem. Lett.

    (2010)
    P.J. Beswick et al.

    Bioorg. Med. Chem. Lett.

    (2010)
    M.H. Abdi et al.

    Bioorg. Med. Chem. Lett.

    (2010)
  • C. Abad-Zapatero

    Expert Opin. Drug Disc.

    (2007)
  • P.D. Leeson et al.

    Nat. Rev. Drug Disc.

    (2007)
    T. Ryckmans et al.

    Bioorg. Med. Chem. Lett.

    (2009)
  • S.A. Hitchcock et al.

    J. Med. Chem.

    (2006)
  • A.W. Wilson et al.

    Eur. J. Pain

    (2006)
  • F. DiVirgilio et al.
  • H.P. Buisman et al.

    Proc. Natl. Acad. Sci. U.S.A.

    (1988)
  • D. Ferrari et al.

    J. Immunol.

    (2006)
  • D. Fields et al.

    Nat. Rev. Neurosci.

    (2006)
  • I.P. Chessel et al.

    Pain

    (2005)
  • P.M. Honore et al.

    J. Pharmacol. Exp. Ther.

    (2006)
  • D.C. Broom et al.

    J. Pharmacol. Exp. Ther.

    (2008)
  • A. Perez-Medrano et al.

    J. Med. Chem.

    (2009)
  • D.W. Nelson et al.

    J. Med. Chem.

    (2006)
  • Cited by (30)

    • ATP-activated P2X7 receptor in the pathophysiology of mood disorders and as an emerging target for the development of novel antidepressant therapeutics

      2018, Neuroscience and Biobehavioral Reviews
      Citation Excerpt :

      Several CNS-penetrable P2X7 antagonists have been developed by GSK, including GSK compound 16, GSK compound 18, GSK compound 21 and GSK1482160 (Table 1). GSK compound 16, GSK compound 18, and GSK compound 21 inhibit the human P2X7 receptor with IC50 values of 8–10 nM and are much less potent at the rat P2X7 receptor with IC50 values of 80 nM, 398 nM and 63 nM in a dye uptake assay, and B/P ratios of 0.23, 0.33 and <0.1, respectively (Abberley et al., 2010; Beswick et al., 2010). GSK1482160 (GSK compound 31: (Abdi et al., 2010)) exhibits IC50 values of 3 nM and 316 nM at the human and rat P2X7 receptors in a dye uptake assay, respectively, and excellent BBB penetrability with a B/P ratio closing to 2.1 (Abdi et al., 2010).

    • The evolution of P2X7 antagonists with a focus on CNS indications

      2016, Bioorganic and Medicinal Chemistry Letters
    View all citing articles on Scopus
    View full text